Evaluating a Single Domain Antibody Targeting Human PD-L1 as a Nuclear Imaging and Therapeutic Agent

Clinical Translation of [68Ga]Ga-NOTA-anti-MMR-sdAb for PET/CT Imaging of Protumorigenic Macrophages

(2019) Catarina Xavier et al.   MOLECULAR IMAGING AND BIOLOGY

Safety profile of avelumab in patients with advanced solid tumors: A pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials

(2018) Karen Kelly et al.   CANCER

Same-Day Imaging Using Small Proteins: Clinical Experience and Translational Prospects in Oncology

(2018) Ahmet Krasniqi et al.   JOURNAL OF NUCLEAR MEDICINE

Immuno-PET Imaging of 89Zr Labeled Anti-PD-L1 Domain Antibody

(2018) Dan Li et al.   MOLECULAR PHARMACEUTICS

A versatile T cell-based assay to assess therapeutic antigen-specific PD-1-targeted approaches

(2018) Maarten Versteven et al.   Oncotarget

Noninvasive imaging of the PD-1:PD-L1 immune checkpoint: Embracing nuclear medicine for the benefit of personalized immunotherapy

(2018) Katrijn Broos et al.   Theranostics

Dendritic Cells and Programmed Death-1 Blockade: A Joint Venture to Combat Cancer

(2018) Maarten Versteven et al.   Frontiers in Immunology

Peptide-Based 68Ga-PET Radiotracer for Imaging PD-L1 Expression in Cancer

(2018) Ravindra A. De Silva et al.   MOLECULAR PHARMACEUTICS

89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer

(2018) Frederike Bensch et al.   NATURE MEDICINE

Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer

(2018) A. N. Niemeijer et al.   Nature Communications

Synthesis and Biologic Evaluation of a Novel18F-Labeled Adnectin as a PET Radioligand for Imaging PD-L1 Expression

(2017) David J. Donnelly et al.   JOURNAL OF NUCLEAR MEDICINE

Non-invasive assessment of murine PD-L1 levels in syngeneic tumor models by nuclear imaging with nanobody tracers

(2017) Katrijn Broos et al.   Oncotarget

PDL1 Signals through Conserved Sequence Motifs to Overcome Interferon-Mediated Cytotoxicity

(2017) Maria Gato-Cañas et al.   Cell Reports

PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome

(2017) Hashem O. Alsaab et al.   Frontiers in Pharmacology

Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade

(2017) Fei Zhang et al.   Cell Discovery

PD-L1 Detection in Tumors Using [64Cu]Atezolizumab with PET

(2016) Wojciech G. Lesniak et al.   BIOCONJUGATE CHEMISTRY

Next generation predictive biomarkers for immune checkpoint inhibition

(2016) Yulian Khagi et al.   CANCER AND METASTASIS REVIEWS

PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations

(2016) Weiping Zou et al.   Science Translational Medicine

A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors

(2016) Samit Chatterjee et al.   Oncotarget

Cancer-Associated Myeloid Regulatory Cells

(2016) Yannick De Vlaeminck et al.   Frontiers in Immunology

Noninvasive Imaging of Tumor PD-L1 Expression Using Radiolabeled Anti-PD-L1 Antibodies

(2015) S. Heskamp et al.   CANCER RESEARCH

Imaging, Biodistribution, and Dosimetry of Radionuclide-Labeled PD-L1 Antibody in an Immunocompetent Mouse Model of Breast Cancer

(2015) Anders Josefsson et al.   CANCER RESEARCH

Phase I Study of 68Ga-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma

(2015) M. Keyaerts et al.   JOURNAL OF NUCLEAR MEDICINE

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

(2015) Antoni Ribas et al.   LANCET ONCOLOGY

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging

(2015) Roy L. Maute et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The future of immune checkpoint therapy

(2015) P. Sharma et al.   SCIENCE

AZD1480 delays tumor growth in a melanoma model while enhancing the suppressive activity of myeloid-derived suppressor cells

(2015) Sarah K. Maenhout et al.   Oncotarget

Immunogenicity of targeted lentivectors

(2015) Cleo Goyvaerts et al.   Oncotarget

Interference with PD-L1/PD-1 co-stimulation during antigen presentation enhances the multifunctionality of antigen-specific T cells

(2014) J J Pen et al.   GENE THERAPY

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

(2014) Thomas Powles et al.   NATURE

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

Nanobody: The “Magic Bullet” for Molecular Imaging?

(2014) Rubel Chakravarty et al.   Theranostics

Synthesis, Preclinical Validation, Dosimetry, and Toxicity of 68Ga-NOTA-Anti-HER2 Nanobodies for iPET Imaging of HER2 Receptor Expression in Cancer

(2013) C. Xavier et al.   JOURNAL OF NUCLEAR MEDICINE

Imaging and radioimmunotherapy of multiple myeloma with anti-idiotypic Nanobodies

(2013) M Lemaire et al.   LEUKEMIA

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

(2013) Omid Hamid et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nanobodies Targeting Mouse/Human VCAM1 for the Nuclear Imaging of Atherosclerotic Lesions

(2012) Alexis Broisat et al.   CIRCULATION RESEARCH

PD-L1 co-stimulation contributes to ligand-induced T cell receptor down-modulation on CD8+T cells

(2011) Katarzyna Karwacz et al.   EMBO Molecular Medicine

Preclinical screening of anti-HER2 nanobodies for molecular imaging of breast cancer

(2011) Ilse Vaneycken et al.   FASEB JOURNAL

Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR–induced stop signal

(2009) Brian T Fife et al.   NATURE IMMUNOLOGY